ESG Report
Environmental | Social | Governance
For the fiscal year ending December 31, 2023
# Table of Contents

## About Aurinia
- 4 Our Mission
- 5 Our Story
- 6 Our People
- 7 About Lupus Nephritis
- 8 About LUPKYNIS®
- 9 LUPKYNIS Clinical Development Program

## Our Approach to Sustainability
- 11 Environmental, Social and Governance Priorities
- 12 Our ESG Goals and Priorities

## Social
- 14 Empowering the Lupus Nephritis Community
- 15 Encouraging Community Engagement
- 16 Patient-Centered Initiatives Through Advocacy and Education
- 17 Education Programs
- 18 Patient Access Through Aurinia Alliance

## Governance
- 19 ENLIGHT-LN® Registry
- 20 Commitment to Safety
- 21 DEI in Action
- 22 Employee Engagement
- 23 Professional Training & Development
- 24 Employees’ Health and Safety

## Environment
- 35 Operational Control Approach for Emissions
- 36 Limiting Emissions Caused by Owned Assets
- 37 Limiting Emissions Caused by Purchased Electricity
- 38 Limiting Emissions Outside of Our Control
- 39 Doing Our Part to Help the Environment
- 40 Managing Our Energy Consumption
- 41 LUPKYNIS Supply Chain

## Appendix
- 43 Scope and Methodology
- 44 Terms and Abbreviations
- 45 Forward Looking Statement
About Aurinia
Our Mission

At Aurinia, our mission is to change the trajectory of autoimmune diseases – especially for people who too often are overlooked, excluded, misunderstood, and left to wait.
Our Story

At Aurinia, we help patients live better lives.

We are addressing some of the toughest challenges in autoimmune disease and are working every day to have a positive impact.

We pursue promising science that redefines the standard of care and offers every patient the opportunity for a better life. Day in and day out, we work hand in hand with the lupus community to eliminate barriers that limit access, equity, and better health outcomes.

Our impact is realized by harnessing everything that makes us unique: our compassion for patients, entrepreneurial spirit, and agile mindset that drives us to think big and get things done.

Together, we can achieve something better.
Our People

We know that it takes courage, passion, and resilience to succeed at Aurinia. That’s why our people are our greatest resource.

Our team thinks big and gets it done. Built for agility, our patient-first mindset, small size, and entrepreneurial culture allows us to be nimble and pivot quickly. We share a collective focus to drive meaningful impact for patients, healthcare providers, and the communities we serve.
Addressing a Severe Autoimmune Disease

We’ve taken on the toughest challenges in autoimmune diseases and are working every day to have a positive impact on patients and their communities. The patient population that we serve has high unmet needs and often faces significant barriers to optimal care.

» Systemic lupus erythematosus (SLE) is a chronic autoimmune disease that causes inflammation and pain in various areas of the body.

» Lupus nephritis, or LN, causes inflammation of the kidneys and is one of the most serious and common complications of SLE.

» LN is associated with a significantly elevated risk of kidney failure, cardiac events, and even death.¹

» People with lupus are 90% female, and the disease is two to three times more prevalent among racial-ethnic minority women.²

» LN prevalence is four times higher for Black and Asian people and two times higher for Hispanic and Native American people.²


We are proud to have developed and successfully launched our first commercial asset LUPKYNIS, a second generation calcineurin inhibitor (CNI) and the first FDA-approved oral therapy for patients with active lupus nephritis (LN).
Robust Clinical Development Program: Positions LUPKYNIS as the New Standard of Care for the Treatment of LN – Unrivalled Efficacy

<table>
<thead>
<tr>
<th>Registrational Studies</th>
<th>Registry / Real World Evidence</th>
<th>Post-marketing Studies</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>AURION</strong></td>
<td><strong>ENLIGHT-LN REGISTRY</strong></td>
<td><strong>LACTATION STUDY</strong></td>
</tr>
<tr>
<td>Proof-of-concept study monitoring 24- and 48-week remission in adult LN patients</td>
<td>Observational registry of LN patients who have initiated treatment with LUPKYNIS in the US (expected readout 2027)</td>
<td>Study investigating the amount of LUPKYNIS excreted in breast milk following a single oral dose of 23.7 mg</td>
</tr>
<tr>
<td><strong>AURA</strong></td>
<td></td>
<td><strong>VOCAL</strong></td>
</tr>
<tr>
<td>Tested LUPKYNIS impact on speed of remission and ORR in LN when used in combination with SoC</td>
<td></td>
<td>Study of LUPKYNIS in adolescents ages 12–18 with LN (expected readout 2027)</td>
</tr>
<tr>
<td><strong>AURORA</strong></td>
<td></td>
<td><strong>PEDS 02</strong></td>
</tr>
<tr>
<td>Ph 3 trial evaluating LUPKYNIS in LN in combination with SoC Confirmatory registrational study leading to approval in 2021</td>
<td></td>
<td>Prospective 52-week open-label efficacy and safety study in LN patients 5–17 years of age (final protocol submission by 2026)</td>
</tr>
<tr>
<td><strong>AURORA-EXT</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Long-term extension study of LUPKYNIS in LN used as a combination with SoC Included biopsy sub-study</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
Our Approach to Sustainability
Investing in Environmental, Social and Governance Priorities

As part of our mission to improve the lives of people with autoimmune diseases, we believe we must take a wholistic approach to strengthen our impact on the communities we serve.

**SOCIAL**
- Labor Practices and Equal Pay
- Employee Wellbeing
- Talent Management and Retention
- Employee Health and Safety
- Employee Engagement, Diversity, Equity, and Inclusion (DEI)
- Customer Privacy and Data Security
- Professional Development

**ENVIRONMENT**
- Emissions
- Energy Management

**GOVERNANCE**
- Business Ethics
- Systemic Risk Management
- Responsible Supply Chain Management

**INDUSTRY-BASED TOPICS**
- Product Quality and Patient Safety
- Access and Affordability
- Community Relations
Measuring Achievement of our ESG Goals

The Governance & Nomination Committee of our Board of Directors is responsible for ensuring our ESG goals are pursued and are assessed periodically.

## ESG PRIORITIES

<table>
<thead>
<tr>
<th>Environment</th>
<th>Social</th>
<th>Governance</th>
</tr>
</thead>
<tbody>
<tr>
<td>Energy &amp; Emissions</td>
<td>Talent Management and Retention</td>
<td>Systemic Risk Management</td>
</tr>
<tr>
<td>Responsible Supply Chain Management</td>
<td>Access and Affordability / Community Relations</td>
<td></td>
</tr>
<tr>
<td>Product Quality and Patient Safety</td>
<td>Product Quality and Patient Safety</td>
<td>Business Ethics</td>
</tr>
<tr>
<td>Labor Practices and Equal Pay</td>
<td>Employee Engagement, DEI</td>
<td></td>
</tr>
<tr>
<td>Employee Wellbeing</td>
<td>Customer Privacy and Data Security</td>
<td></td>
</tr>
<tr>
<td>Employee Health and Safety</td>
<td>Customer Privacy and Data Security</td>
<td></td>
</tr>
</tbody>
</table>

## GOALS

<table>
<thead>
<tr>
<th>Environment</th>
<th>Social</th>
<th>Governance</th>
</tr>
</thead>
<tbody>
<tr>
<td>Energy &amp; Emissions</td>
<td>Promote reduction of emissions to reduce our carbon footprint and improve air quality</td>
<td>Ensure continuous monitoring and risk management improvement</td>
</tr>
<tr>
<td>Responsible Supply Chain Management</td>
<td>Build and maintain a resilient and sustainable supply chain</td>
<td></td>
</tr>
<tr>
<td>Talent Management and Retention</td>
<td>Retain talent and promote professional development</td>
<td></td>
</tr>
<tr>
<td>Access and Affordability / Community Relations</td>
<td>Transform people’s lives by addressing critical health needs in autoimmune, kidney and rare diseases</td>
<td></td>
</tr>
<tr>
<td>Product Quality and Patient Safety</td>
<td>Deliver high quality products ensuring safety and efficacy</td>
<td></td>
</tr>
<tr>
<td>Labor Practices and Equal Pay</td>
<td>Respect and protect our people</td>
<td></td>
</tr>
<tr>
<td>Employee Engagement, DEI</td>
<td>Retain talents and promote professional development</td>
<td></td>
</tr>
<tr>
<td>Employee Wellbeing</td>
<td>Promote diversity and inclusion within the workforce</td>
<td></td>
</tr>
<tr>
<td>Customer Privacy and Data Security</td>
<td>Promote employees’ health and wellbeing</td>
<td></td>
</tr>
<tr>
<td>Employee Health and Safety</td>
<td>Promote continuous improvement of information technology systems and management data protection</td>
<td></td>
</tr>
<tr>
<td>Business Ethics</td>
<td>Ensure high quality of health and safety standards</td>
<td></td>
</tr>
<tr>
<td>Systemic Risk Management</td>
<td>Outline expectations for business conduct and emphasize the importance of ethical behavior</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Enhance ESG leadership</td>
<td></td>
</tr>
</tbody>
</table>
Social
Empowering the Lupus Nephritis Community

Through our various educational and disease management programs, we encourage people living with LN to take charge of their health through early diagnosis, routine management, and treatment, with a focus on:

- **Safety**
- **Science**
- **Education**
- **Advocacy**
- **Access**
Encouraging Community Engagement

**Elevate Awareness**
- Creating and implementing social media campaigns that drive urgency to diagnose and treat LN
- Showcasing patient stories that highlight possible manifestations of LN and/or journeys through diagnosis and treatment of LN
- Participating in awareness month campaigns such as Kidney Awareness Month and Lupus Awareness Month

**Address Access Barriers**
- Implementing innovative programs such as patient navigation that addresses social determinants of health through an individualized approach
- Designing surveys that drive thoughtful responses surrounding the unmet needs of the LN community
- Developing and distributing our resources that address socioeconomic barriers (transportation, language barriers, technology, etc.)
- Supporting Legislative (federal and local) campaigns that address access hurdles for patients and providers

**Community Support**
- Engaging in charitable giving and volunteer programs for causes that are important to our community
- Creating community-focused programs and events that benefit those in need of our support
- Listening to our employees and encouraging them to bring forth worthy causes to advocate for
- Building meaningful relationships and striving to continue our engagement with our communities
Developing Patient-Centered Initiatives Through Advocacy and Education

We collaborate with industry and patient advocacy groups to increase awareness, enable earlier diagnosis, advance the development of potential new therapies, and design initiatives that address the unique challenges of patient communities.

Aurinia throughout 2023:
- collaborated with more than 60 advocacy organizations
- executed 42 patient disease state awareness (DSA) programs
- and connected with 2,215 people living with SLE/LN
ALL IN for LN seeks to connect the LN community and encourage people living with lupus to seek routine check-ups to catch the disease early, which may help prevent irreversible kidney damage and other serious complications. The program also offers free information and resources, in addition to an LN Awareness Kit. ALL IN for LN’s Facebook community helps connect others who are also affected by lupus and LN.

Get Uncomfortable with LN addresses the need for routine testing for LN and enables users to find rheumatologists or nephrologists through its doctor finder tool. In 2023, Aurinia partnered with entertainer and entrepreneur Toni Braxton to share her personal lupus journey to empower people with lupus and lupus nephritis to prioritize their kidney health.
Ensuring Patient Access Through Aurinia Alliance

We invest heavily in resources, processes, and infrastructure aimed at improving access to vital treatment options.

Aurinia Alliance provides people living with lupus nephritis and their care partners with personalized support through education, tools, and resources.

Educational Resources
Finding reliable information about LN can be difficult. Our goal is to empower people living with LN through education so they can feel confident advocating for themselves.

Financial Assistance
Navigating a treatment plan for LN can come with concerns about whether you’ll be able to afford Aurinia medication. We offer options for patients to contact us to find out what financial assistance options may be available to them.

Aurinia Treatment Support
Living with a serious disease can sometimes feel like a lot to manage. We help patients stay organized, informed and on top of their Aurinia treatment schedule.
Maximizing
LUPKYNIS’
Benefit and Impact

We provide up-to-date safety information on our medicine, to ensure the highest quality.

To track the impact of LUPKYNIS, we initiated ENLIGHT-LN®, a U.S-based prospective, observational registry designed to characterize the real-world effectiveness profile and utilization patterns of voclosporin in the U.S.

The registry supports the interests of patients, clinicians, regulatory bodies, payers and industries by obtaining longitudinal data on LUPKYNIS.
Our Commitment to Safety

At Aurinia, we are deeply committed to the safety and well-being of the communities we serve. With support from patients, family members, caregivers, and healthcare providers, we provide up-to-date safety information and ensure the highest quality for our medicines.

This includes collecting, assessing, and reporting all adverse events (AEs, or side effects) and product quality complaints (PQCs) associated with the use of our products.

To learn how to report an adverse event, visit https://www.auriniapharma.com/contact-us#report-event
Encouraging Diverse Thinking and Ideas

Diversity, Equity, and Inclusion (DEI)

We strive to create an environment that accelerates diverse thinking and ideas into scientific breakthroughs and building a sustainable company. We value every voice and respect every perspective as we unravel the challenges inherent in developing groundbreaking therapies for patients from many cultures and geographies. We are committed to cultivating a highly engaged workforce by continually incorporating authentic diversity, equity, equality, and inclusion efforts into our behaviors and culture to create an organization rich with ideas, perspectives, and experiences.

All employees are required to complete an annual training related to diversity inclusive of age, race, color, gender, sexual preference, nationality, or physical ability.

Our DEI journey is led by four primary drivers:

- People
- Culture
- Capabilities and Governance
- Market

For each of these pillars, we have developed a detailed plan and actions to achieve our goals.
Advancing Aurinia’s bold mission and vision through an engaged workforce

Aurinia partnered with Gallup to conduct its first employee Engagement & Inclusion survey designed to assess overall employee engagement and illuminate where engagement can be enhanced.

The anonymous survey evaluated four key factors – Basic Needs, Individual Contribution, Teamwork, Growth, and Inclusion.

With over 93% of employees participating in the survey, we found that we have a highly engaged workforce and gained new insights to further improve employee engagement.

Definition of Employee Engagement:
The level of involvement, enthusiasm, and commitment an employee has towards their work and their organization.

The survey data is being used to start an ongoing internal dialogue, action planning and measurement that will:

- Enable leadership to understand and improve company-wide engagement levels.
- Seek employee ideas to sustain areas of strength and improve gaps.
- Turn ideas into actionable strategies that align with Aurinia’s Values and prioritize purpose, ownership, and accountability.
- Continue building a culture of engagement, inclusion, and performance excellence.
Commitment to Professional Training & Development

Developing employees’ skills and capabilities align with our commitment to investing in our people, as well as our commitment to quality and safety. It also ensures we have the right talent in the right places across the organization to be successful.

Developing Employee Competencies

In 2023 we conducted a needs analysis, based on our competency model. As a result, we offered new training to all employees on topics such as collaboration, communication, and listening. We also offered programs on engagement, performance management, and launched a popular “Talk About” series where employees learn about different groups at Aurinia and how they contribute to our Vision and Mission.

Developing our managers continues to be an important priority. In 2023 we piloted a program dedicated to that population, Dynamic Leadership @ Aurinia. The focus of this interactive, multi-week program is to develop an authentic leadership style grounded in Aurinia’s values. Participant feedback about the program was outstanding and the program will continue to be offered in 2024.

Regulatory and Compliance Training

We provide our employees with developmental training in accordance with their specific role and career path, paying considerable attention to any new upcoming regulations and procedures. Note that the hours of training listed in the box on the right do not include hours spent in regulatory and compliance trainings for all employees.

LinkedIn Learning

LinkedIn Learning, a self-directed learning and development platform, continues to be available for all employees. It provides more than 16,000 courses and other resources for employees to further develop skillsets that can enhance their performance and personal and professional value. We have created a list of curated LinkedIn Learning courses to promote visibility to those aligned with Aurinia’s business needs, values, and competencies.

Our staff participated in

1,369 hours of professional training in 2023
Prioritizing Employees’ Health and Safety

Our employees’ health, safety, and overall wellbeing is a top priority for us. We track this in a variety of ways, including providing all our employees access to healthcare benefits, measuring the number of employees participating in our health and wellness events, ensuring 100% of our employees are covered by an occupational health and safety management system, and minimizing work-related injuries.

We are committed to maintaining compliance with all legal and regulatory requirements in the countries we operate.

In FY2023, there were no work-related injuries.
Governance
Maintaining the Commitment to Best Practices

We understand that adhering to established best practices of corporate governance is critical to earning and maintaining the trust of our shareholders, customers, employees, and other stakeholders, and is essential to building long-term value. Our Governance and Nomination Committee is responsible for developing our approach to environmental, social, and governance issues and implementing high standards of corporate governance practices. Our CEO and CFO are also responsible for leading and managing our approach to corporate social responsibility.

An effective control system enables companies to pursue their objectives consistently through informed decisions. As part of our commitment, we established a consistent monitoring and control system across operations. This includes internal controls over financial reporting, Good Manufacturing Practices (GMPs), quality control and assurance within our supply chain, accuracy of government reporting and routine internal audits over key functions of our business.

<table>
<thead>
<tr>
<th>ESG area</th>
<th>Sustainability Topic</th>
<th>Policies and Procedures</th>
</tr>
</thead>
<tbody>
<tr>
<td>Environment</td>
<td>• Emissions&lt;br&gt;• Energy Management</td>
<td>• LEED (Leadership in Energy and Environmental Design) Building Certificates</td>
</tr>
<tr>
<td>Social</td>
<td>• Labor Practices and Equal Pay&lt;br&gt;• Employee Wellbeing&lt;br&gt;• Talent Management and Retention&lt;br&gt;• Employee Health &amp; Safety&lt;br&gt;• Employee Engagement, DEI&lt;br&gt;• Customer Privacy and Data Security</td>
<td>• Code of Ethics&lt;br&gt;• Diversity Policy&lt;br&gt;• Corporate Performance System&lt;br&gt;• Information Security Policy&lt;br&gt;• Acceptable Use Policy&lt;br&gt;• Data Protection and Classification Policy&lt;br&gt;• Data Privacy Policy&lt;br&gt;• Quality Management System</td>
</tr>
<tr>
<td>Governance</td>
<td>• Business Ethics&lt;br&gt;• Systemic Risk Management&lt;br&gt;• Responsible Supply Chain Management</td>
<td>• Business Continuity Program&lt;br&gt;• Health and Wellness program&lt;br&gt;• Whistleblower Policy&lt;br&gt;• Code of Ethics&lt;br&gt;• Bullying and Harassment Policy&lt;br&gt;• Financial Reporting Controls&lt;br&gt;• Fraud Policy&lt;br&gt;• Corporate Disclosure Policy</td>
</tr>
</tbody>
</table>
Enforcing Our Corporate Code of Ethics and Conduct

The foundation of our corporate governance principles and practices are built on our reputation for openness, integrity, and accountability. It is these principles that guide us every day.

We have adopted a Corporate Code of Ethics and Conduct, applicable to all of our employees, executive officers and directors. The Code of Conduct is also available on our website.

Each of our employees are expected to be familiar with and at least must acknowledge their understanding of our code of conduct annually. In FY2023, 100% of our employees completed the Corporate Code of Ethics and Conduct training. Additionally, every employee must complete healthcare compliance training on an annual basis. Our commercial field personnel and home personnel must be trained on healthcare compliance annually; in FY2023, 100% of our employees completed modules one and two of our healthcare compliance.

Audit Committee

The Audit Committee of our Board of Directors is responsible for monitoring the implementation of the Code of Conduct and must approve any material changes to or waivers of the Code of Conduct regarding our directors or executive officers, and disclosures made in our annual report in such regard. In addition, we intend to post on our website all disclosures that are required by law or the listing standards of the applicable stock exchange concerning any amendments to, or waivers from, any provision of the Code of Conduct. There have been no waivers from the Code of Conduct sought or granted.

The Code of Conduct is part of our commitment to adhere to the highest levels of ethical, compliance and legal standards. Detailed information on other aspects of our corporate governance policies and programs, which include our Fraud Policy, are available on our website. In addition to these corporate governance policies, we also maintain written policies and procedures that are established to ensure all of our interactions with health care practitioners are ethical and in line with ever evolving laws and guidance in each of the jurisdictions in which we operate. Each of these are reviewed on a regular basis to ensure they are up to date, and all applicable members of our team are trained on them.

Compliance Training Completion Rates for FY2023

<table>
<thead>
<tr>
<th>Compliance Training</th>
<th>Completion Rate</th>
</tr>
</thead>
<tbody>
<tr>
<td>Code of Conduct</td>
<td>100%</td>
</tr>
<tr>
<td>Healthcare Compliance Modules</td>
<td>100%</td>
</tr>
<tr>
<td>Data Privacy</td>
<td>100%</td>
</tr>
</tbody>
</table>
Fostering a Culture of Openness, Integrity, and Accountability

To help foster a culture of openness, integrity, and accountability, we have a Board of Directors that is comprised of accomplished leaders from various backgrounds and a breadth of experience in scientific and corporate matters. They set our goals and make determinations on material business initiatives and decisions, as well as set the direction for our business.

Governance and Nomination Committee

Our Governance & Nomination Committee of our Board of Directors is responsible for monitoring ESG matters, as laid out in our Corporate Governance Charter. The Committee will develop and monitor our approach to ESG issues and, subject to approval by the Board, to implement and administer a system of corporate governance which reflects best practices in corporate governance.

This Committee reports annually to our shareholders through our annual proxy and management information circular to shareholders. These reports are made in accordance with applicable securities laws, on our system of corporate governance, and the operation of its system of governance. Though our employees have not formally been delegated responsibility for management of sustainability-related topics or impact management in our corporate governance, each employee has a role in advancing ESG within Aurinia.

Independence of the Board of Directors

Our Board has determined that all our directors, except Peter Greenleaf and Robert Foster, are independent directors, as defined under applicable Nasdaq and Canadian rules. In making such a determination, our Board considered the relationships that each such non-employee director has with our company and all other facts and circumstances that our Board deemed relevant in determining his or her independence, including the beneficial ownership of our capital stock by each non-employee director.

Peter is considered to have a material relationship with Aurinia by virtue of being the President and CEO. Dr. Foster is considered to have a material relationship due to an ongoing deferred compensation arrangement between the Company and Dr. Foster.

Also, there are no family relationships among any of our directors or executive officers. We disclose detailed information in our US Securities and Exchange Commission (SEC) filings available on our corporate website. In addition, to avoid potential conflicts of interest, Dr. Daniel Billen, Director and Chairman of the Board, is not an executive.
Board Diversity

We have adopted a written Diversity Policy, which focuses on the identification and nomination of directors and executive officers, and requires that the Board of Directors consider diversity on the Board from several aspects, including but not limited to gender, age, ethnicity and cultural diversity. In addition, when assessing and identifying potential new members to join the Board of Directors or our executive team, the Board shall consider the current level of diversity on the Board and the executive team. The Board has followed our Diversity Policy in considering potential candidates for election and appointment of members of the Board and the executive team.

The Governance & Nomination Committee of the Board of Directors regularly considers our Diversity Policy and our diversity needs, and reports to the Board as needed on our advancements related to this policy. In connection with such reviews, the Governance & Nomination Committee will consider the effectiveness of our approach to diversity and will recommend to the Board any changes that it considers appropriate. The Board continues to seek more diversity on the Board and in senior executive positions.

The table on the right sets out voluntarily disclosed information regarding certain diversity elements for our Board of Directors.

<table>
<thead>
<tr>
<th>Country of Principal Executive Office</th>
<th>Canada</th>
</tr>
</thead>
<tbody>
<tr>
<td>Foreign Private Issuer</td>
<td>No</td>
</tr>
<tr>
<td>Disclosure Prohibited under Home Country Law</td>
<td>No</td>
</tr>
<tr>
<td>Total Number of Directors</td>
<td>9</td>
</tr>
</tbody>
</table>

**Part I: Gender Identity**

<table>
<thead>
<tr>
<th>Gender</th>
<th>Female</th>
<th>Male</th>
</tr>
</thead>
<tbody>
<tr>
<td>Directors</td>
<td>3</td>
<td>6</td>
</tr>
</tbody>
</table>

**Part II: Age Group**

<table>
<thead>
<tr>
<th>Age</th>
<th>&lt; 30</th>
<th>30-50</th>
<th>&gt; 50</th>
</tr>
</thead>
<tbody>
<tr>
<td>Directors</td>
<td>0</td>
<td>1</td>
<td>8</td>
</tr>
</tbody>
</table>

**Part III: Demographic Background**

<table>
<thead>
<tr>
<th>Demographic Background</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Underrepresented in Home Country Jurisdiction</td>
<td>0</td>
</tr>
<tr>
<td>LGBTQ+</td>
<td>0</td>
</tr>
<tr>
<td>Did Not Disclose Demographic Background</td>
<td>1</td>
</tr>
</tbody>
</table>
Evaluating Corporate Risks

As a pharmaceutical company whose main priority is helping patients, we have a proactive approach to addressing risk, helping to safeguard the long-term sustainability of our business.

We follow all applicable regulations and laws according to the industry in which we work, and the jurisdictions in which we operate. This extends to our corporate risk management approach. Our evaluation of corporate risks ensures that we meet our strategic objectives while ensuring a responsible management of our business.

Annually, our executive team members, Board of Directors, and members of primary departments identify risks, their severity, and their likelihood, in addition to key mitigation strategies.

Business Continuity Program

Aurinia annually conducts a business continuity exercise, with our team members from various departments. The purpose of this exercise is to invest in our long-term feasibility and identify risk areas we can address.

During our 2023 exercise with our team members, we identified:

» Critical processes in place
» Business continuity plans

In addition, we updated our risk register for the following:

» Human Capital / Culture
» Portfolio
» Cyber / Information Security
» Third Party Relationship Management
» Commercial Execution
» Compliance
» Supply Chain
» Litigation

Please read the section risk factors in our most recently filed annual report on Form 10-K, filed in February 2024, for further information and detail regarding the risks we have identified associated with our business. By identifying these risks in our Business Continuity Program, we hope to continue to fulfill our purpose as a company by continuing to deliver pharmaceuticals that improve our patients’ lives.
Following the Information Security Policy

The Information Security Policy, in line with best practices such as GDPR (EU General Data Protection Regulation), manages and executes the information security framework for preserving the confidentiality, integrity, availability, and privacy of our information assets. Routine information security training and updates are rolled out to the employee population and metrics are tracked to ensure we have a strong security posture. To uphold this, we aim to have at least 95% of employees trained on data security and acknowledge our privacy policy annually. In FY 2023, our employees totaled 1,581 hours of cybersecurity training. For data privacy, 100% of our employees completed this training. An information security update is provided quarterly to the Audit Committee, with a detailed review provided at least annually.

With reference to cybersecurity, we are committed to protecting our information technology systems and have adopted a robust plan and an Information Security Policy. We maintain an appropriate level of cybersecurity and ransomware insurance that is reviewed and renewed annually.
Duties and Responsibilities of the Board and Executives in Sustainability Reporting

According to our Corporate Governance Charter, the duties and responsibilities of the Governance & Nomination Committee of our Board of Directors include the following key responsibilities:

Firstly, to develop and monitor our overall approach to environmental, social and corporate governance issues and, subject to approval by the Board, to implement and administer a system of corporate governance which reflects best practices.

Secondly, to report annually to our shareholders, through our annual proxy and management information circular to shareholders in accordance with applicable securities laws, on our system of corporate governance and the operation of its system of governance.

Thirdly, to analyze and report to the Board the relationship of each director to Aurinia and significant shareholders as to whether such a director is an independent director.

Finally, to advise the Board or any of the committees of the Board of any corporate governance issues which the Governance & Nomination Committee determines ought to be considered by the Board or any such committee. And to review with the Board, as required, but not less than annually, the role of the Board, the terms of reference of each of the committees of the Board and the methods and processes by which the Board fulfills its duties and responsibilities. Please view our Corporate Governance Charter for further information.
Overseeing Our Risk Management Process

Role of the Board in Risk Oversight

One of the key functions of our Board is informed oversight of our risk management process. Our Board does not have a standing risk management committee, but rather administers this oversight function directly through the Board of Directors as a whole, as well as through various standing committees of our Board that address risks inherent in their respective areas of oversight. Our Audit Committee of the Board is responsible for overseeing the management of risks associated with our financial reporting, accounting, and auditing matters, as well as business-related risks (such as leadership, continuity, health and safety of employees, and matters relating to our clinical trials), reviewing as required our processes around the management and monitoring of such risks, as well as conducting a risk assessment review.

Our Audit Committee also receives regular reports in respect to our cyber security awareness and processes. Both the Board as a whole and the various standing committees receive periodic reports from the standing committees, as well as incidental reports as matters may arise. It is the responsibility of the committee chairs to report findings regarding material risk exposures to the Board as quickly as possible.
Environment
Following the Operational Control Approach for Emissions

Another ESG priority we have identified is our greenhouse gas (GHG) emissions. GHG emissions occur because of fuels being burned as a result of our operations. There are three scopes of emissions: scope 1, 2, and 3. Scope 1 includes emissions caused by owned assets, such as company vehicles, offices, and generators. Scope 2 covers emissions resulting from our purchased electricity. Because we lease all our corporate offices, the electricity purchased for these offices falls into Scope 2 emissions. Scope 3 involves activities outside of our control, such as downstream and upstream activities. We have focused on measuring our Scope 1 and 2 footprint. We follow the operational control approach for emissions, which includes only emissions sources that we have full control over. The GHG Protocol has been applied for the calculation of our GHG emissions.

Three Scopes Of Emissions:

- **Scope 1**: Owned Assets
- **Scope 2**: Purchased Electricity
- **Scope 3**: Upstream and Downstream
Limiting Emissions Caused by Owned Assets

Scope 1 emissions are calculated by taking the emissions caused by owned assets and multiplying this figure with an emissions factor.

Aurinia does not have any owned assets that cause GHG emissions, therefore are no Scope 1 emissions to disclose for FY2023. If assets that cause emissions are acquired, this will be disclosed in future reports.
Limiting Emissions Caused by Purchased Electricity

**Scope 2**

Purchased Electricity

Scope 2 emissions that result from the generation of purchased electricity consumed by us are an additional priority. There are two allocation methods of calculating Scope 2 emissions: Market-based and Location-based. (See right)

**Market-Based**

The market-based method measures emissions based on the agreed energy mix between the energy provider and Aurinia. Because our building owners are unable to provide us with the breakdown of renewable to non-renewable energy provided by the energy company, we were not able to calculate market-based Scope 2 emissions for FY2023.

**Location-Based**

The location-based method uses the average emissions intensity of grids where the energy consumption occurs. We have consolidated our blueprint into two centralized locations that are in Edmonton, Alberta and Rockville, Maryland which will help minimize travel and transportation.

To measure our Location-based Scope 2 emissions, because our building owners only provide a general utilities expenditure without a specific energy usage breakdown for our office spaces, we calculated our usage using the area method with data provided by the US Energy Information Administration for our Rockville, Maryland office, and from the Government of Canada’s Comprehensive Energy Use Database for our office in Canada. (See next page for more information on our calculation process)

**Results**

The data in the table on the right with our total emissions for FY2023 (table 15) has been presented in metric tons of carbon dioxide equivalents (mtCO2e) for comparability purposes; the US EIA data and Government of Canada’s data includes carbon dioxide (CO2), methane (CH4), and nitrous oxide (N2O), emissions adjusted using global warming potential values from the fourth Intergovernmental Panel on Climate Change (IPCC) assessment. Including CO2 equivalents ensures that all emissions are accounted for.

<table>
<thead>
<tr>
<th>Emissions</th>
<th>Amount</th>
</tr>
</thead>
<tbody>
<tr>
<td>Scope 2</td>
<td>Emissions (mtCO2e)</td>
</tr>
<tr>
<td>Rockville, Maryland</td>
<td>149.61</td>
</tr>
<tr>
<td>Edmonton, Alberta, Canada</td>
<td>68.82</td>
</tr>
<tr>
<td>Total</td>
<td>218.43</td>
</tr>
</tbody>
</table>

Our Scope 2 emissions, as shown in the above table, were calculated by using the area method. This method involved estimating our energy usage per square foot via research provided by government sources. After we determined our estimated energy usage, we multiplied this figure by grid emissions factors provided by the US Environmental Protection Agency’s (EPA) eGrid for the state of Maryland for our Rockville office, and Canada’s National Inventory Report for grid emissions factors for our Canadian offices. The state of Maryland’s grid emits less CO2e per kWh compared to grids across the US and in rural regions of Canada.

The resulting total emissions, as illustrated in the previous table, are 218.43 metric tons of CO2e. The respective emissions intensity of our Scope 1 and 2 impact is $0.001 cents per kg CO2e, which has been calculated by taking our total emissions in kilograms divided by our revenue for FY2023. This calculation includes all GHGs.
Limiting Emissions Outside of Our Control

Our Scope 3 footprint comes from employee commuting, business travel, transportation, and activities along our supply chain.

Because most of our emissions fall into Scope 3, measuring and reducing our impact will be an area of concentration in the coming years. The company makes an effort to limit business travel when applicable through the use of video conferencing.

As information from our building owners becomes more available, our GHG emissions calculations will become more precise. We have calculated our emissions using the best available data and have consulted national government sources to estimate energy usage and emissions factors to the best of our ability.
Doing Our Part to Help the Environment

We seek to improve the health and sustainability of our planet, as the wellbeing of our planet directly impacts the health of humanity. We recognize that energy, water, materials use, greenhouse gas emissions, material and hazardous waste, and transportation are among the largest contributors to our environmental footprint. Many of our impacts on the planet are indirect – for instance, we do not manufacture the drug product, the capsules, or the packaging for LUPKYNIS ourselves, but instead do so through our manufacturing partners located across the globe. Similarly, we use a third-party logistics firm to transport LUPKYNIS to specialty pharmacies and specialty distributors directly, who then in turn dispenses LUPKYNIS to patients and hospitals. These contribute to our Scope 3 emissions as a result.

However, although our direct impact on the environment may be small, we take our direct and indirect role in environmental protection matters very seriously. As a first step to assess our impact, our facilities, manufacturing, supply chain and procurement teams began a process of collecting data across these areas. Our next steps will be to establish better tracking and measurement tools, refine strategies, and determine targets to drive our, and our partners’ environmental performance. This process will enable us to increase our internal and external transparency and report progress against specific goals.
Managing Our Energy Consumption

Our energy consumption is an ESG priority that we look for opportunities to improve upon in the coming years. Currently, our Rockville, Maryland office is certified LEED Silver. LEED is short for Leadership in Energy and Environmental Design and is used to recognize sustainable architecture. The types of buildings that are LEED certified are designed with the environment in mind: they consume less resources, create less waste, and emit fewer emissions compared to standard buildings. In addition, LEED-certified buildings have higher indoor air quality and have the added benefit of reducing our energy costs.

Because all of our offices are leased buildings, we are not able to calculate the precise amount of electricity our leased space has used, in addition to the renewable/non-renewable energy ratio of this electricity. This is a metric that can be calculated by working with our building owners to provide us with specific energy usage for our leased offices.

The table below contains estimated energy usage based on the area method using data provided by Bridge Commercial Real Estate for the Maryland office, and from the Government of Canada’s Comprehensive Energy Use Database for an estimate for our Edmonton, Alberta office location. Because our offices use heating and cooling systems that run on electricity, there are no heating, cooling, or steam consumption measures to report. Regarding electricity, heating, cooling, and steam sold, we do not sell any form of energy, therefore, this measurement is not applicable.

<table>
<thead>
<tr>
<th>Energy</th>
<th>Electricity (kWh)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Rockville, MD (LEED Silver)</td>
<td>570,203.48</td>
</tr>
<tr>
<td>Edmonton, AB</td>
<td>111,413.15</td>
</tr>
<tr>
<td><strong>Total</strong></td>
<td><strong>681,616.63</strong></td>
</tr>
</tbody>
</table>

LEED certified buildings use about 25% less energy compared to normal buildings according to the US Department of Energy.
Getting LUPKYNIS to Patients

Current Supply Chain
In order to supply commercial inventory for LUPKYNIS and semi-finished products, we have established relationships with contract manufacturing organizations (CMOs), coupled with supply agreements, for the manufacturing of active pharmaceutical ingredient or drug substance, encapsulation of voclosporin 7.9 mg capsules as well as packaging of LUPKYNIS commercial cartons. Voclosporin requires a specialized drug substance manufacturing process and is manufactured in Visp, Switzerland. The drug substance is then sent to a different CMO in St. Petersburg, FL for formulation and encapsulation. After completion, capsules are then sent to another CMO in Philadelphia, PA for USA commercial packaging.

Future Supply Chain
We are focused on enhancing our supply chain logistics by increasing resilience to change and improving efficiency. The aim is to shorten the overall journey of the final product, with significant reduction in the cost of goods and carbon footprint. We are working towards changes in the delivery of LUPKYNIS outside of the US, which, if implemented, could significantly reduce kilometers traveled.

We plan to achieve a significant reduction in our carbon footprint through changes to the supply chain in the EU and the US that will shorten routes. This will dramatically reduce our GHG emissions, costs, and risks.

*All suppliers in this graphic are third-party suppliers*
Appendix
Scope & Methodology

Aurinia Pharmaceuticals Inc. (Aurinia) is domiciled in Canada, please see our website for more information. We have multiple employees in three countries, including the United States, United Kingdom and Canada. We also have a global reach through our ex-US partnership with Otsuka Pharmaceutical Co., LTD (Otsuka). However, this report includes Aurinia and its subsidiaries on a consolidated basis.

This ESG report is our second publication and has been developed in reference to the GRI Standards. We report annually in alignment with our financial report and include the same group of entities covered in our financial reporting for the fiscal year ended December 31st, 2023.

This ESG report has not been externally assured by a third party, as it is not required; our entire Executive Management Team reviews the report before its annual publishing. Questions regarding the report can be directed to corporateaffairs@auriniapharma.com.
<table>
<thead>
<tr>
<th>Page</th>
<th>Abbreviation</th>
<th>Definition</th>
</tr>
</thead>
<tbody>
<tr>
<td>4</td>
<td>FDA</td>
<td>U.S. Food and Drug Administration</td>
</tr>
<tr>
<td>4</td>
<td>LN</td>
<td>Lupus Nephritis</td>
</tr>
<tr>
<td>6</td>
<td>SLE</td>
<td>Systematic Lupus Erythematosus</td>
</tr>
<tr>
<td>10</td>
<td>DEI</td>
<td>Diversity, Equity, and Inclusion</td>
</tr>
<tr>
<td>11</td>
<td>ESG</td>
<td>Environmental, Social, Governance</td>
</tr>
<tr>
<td>17</td>
<td>DSA</td>
<td>Disease state awareness</td>
</tr>
<tr>
<td>21</td>
<td>AEs</td>
<td>Adverse effects</td>
</tr>
<tr>
<td>21</td>
<td>PQCs</td>
<td>Product quality complaints</td>
</tr>
<tr>
<td>33</td>
<td>GMP</td>
<td>Good Manufacturing Practices</td>
</tr>
<tr>
<td>33</td>
<td>LEED</td>
<td>Leadership in Energy and Environmental Design</td>
</tr>
<tr>
<td>35</td>
<td>SEC</td>
<td>U.S. Securities and Exchange Commission</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Page</th>
<th>Abbreviation</th>
<th>Definition</th>
</tr>
</thead>
<tbody>
<tr>
<td>38</td>
<td>GDPR</td>
<td>EU General Data Protection Regulation</td>
</tr>
<tr>
<td>42</td>
<td>kWh</td>
<td>Kilowatt hours</td>
</tr>
<tr>
<td>43</td>
<td>GHG</td>
<td>Greenhouse gas</td>
</tr>
<tr>
<td>45</td>
<td>mtCO2e</td>
<td>Metric tons of carbon dioxide equivalent</td>
</tr>
<tr>
<td>45</td>
<td>CO2</td>
<td>Carbon Dioxide</td>
</tr>
<tr>
<td>45</td>
<td>CH4</td>
<td>Methane</td>
</tr>
<tr>
<td>45</td>
<td>N20</td>
<td>Nitrous oxide</td>
</tr>
<tr>
<td>45</td>
<td>IPCC</td>
<td>Intergovernmental Panel on Climate Change</td>
</tr>
<tr>
<td>46</td>
<td>EPA</td>
<td>Environmental Protection Agency</td>
</tr>
<tr>
<td>48</td>
<td>CMO</td>
<td>Contract Manufacturing Organization</td>
</tr>
</tbody>
</table>
Cautionary statement regarding forward-looking information

Certain statements made in this report may constitute forward-looking information within the meaning of applicable Canadian securities law and forward-looking statements within the meaning of applicable United States securities law. These forward-looking statements or information include but are not limited to statements or information with respect to: Aurinia’s estimates as to the timeline of milestones for its clinical trials; Aurinia’s ESG goals; Aurinia’s identified key risk areas; Aurinia’s plans to significantly reduce its carbon footprint through changes to the supply chain in the EU and the US; the estimated patient population for lupus nephritis; the results of Aurinia’s clinical trials; It is possible that such results or conclusions may change based on further analyses of these data. Words such as “anticipate,” “will,” “believe,” “estimate,” “expect,” “intend,” “target,” “plan,” “goals,” “objectives,” “may” and other similar words and expressions, identify forward-looking statements.

We have made numerous assumptions about the forward-looking statements and information contained herein, including among other things, assumptions about the patient population for LN; the size of the LN market; the accuracy of results from our clinical trials; the accuracy of reported data from third party studies and reports; that Aurinia’s intellectual property rights are valid and do not infringe the intellectual property rights of other parties; estimated travel requirements and distribution efficiencies; speed of enrolment in our trials and patient adherence to them; and that our suppliers and contractors will meet their contracted requirements. Even though the management of Aurinia believes that the assumptions made, and the expectations represented by such statements or information are reasonable, there can be no assurance that the forward-looking information will prove to be accurate.

Forward-looking information by their nature are based on assumptions and involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of Aurinia to be materially different from any future results, performance or achievements expressed or implied by such forward-looking information. Should one or more of these risks and uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those described in forward-looking statements or information. Such risks, uncertainties and other factors include, among others, the following: difficulties we may experience in completing the commercialization of LUKYNIS; the market and patient population for the LN business may not be as estimated; Aurinia may have to pay unanticipated expenses; Aurinia not being able to extend or fully protect its patent portfolio for LUPKYNIS; competitors may arise with similar products; Aurinia may not be able to obtain sufficient supply to meet commercial demand for LUPKYNIS in a timely fashion; the results from our clinical studies and from third party studies and reports may not be accurate; and our assets or business activities may be subject to disputes that may result in litigation or other legal claims. Although we have attempted to identify factors that would cause actual actions, events or results to differ materially from those described in forward-looking statements and information, there may be other factors that cause actual results, performances, achievements or events to not be as anticipated, estimated or intended. Also, many of the factors are beyond our control. There can be no assurance that forward-looking statements or information will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, you should not place undue reliance on forward-looking statements or information. Except as required by law, Aurinia will not update forward-looking information.

All forward-looking information contained in this presentation is qualified by this cautionary statement. Additional information related to Aurinia, including a detailed list of the risks and uncertainties affecting Aurinia and its business, can be found in Aurinia’s most recent Annual Report on Form 10-K available by accessing the Canadian Securities Administrators’ System for Electronic Document Analysis and Retrieval (SEDAR) website at www.sedar.com or the U.S. Securities and Exchange Commission’s Electronic Document Gathering and Retrieval System (EDGAR) website at www.sec.gov/edgar